Trial Profile

RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 22 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RD 13 (Primary)
Indications Precursor T-cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions

Most Recent Events

17 Jan 2025 According to Bioheng Therapeutics media release, the company will present data from this study as an oral presentation at the 66th American Society of Hematology (ASH) Annual Meeting. The conference will take place from December 7-10, 2024, in San Diego, USA.
13 Dec 2022 Results (n=10) assessing explored the efficacy and safety of CD7-targeted UCAR-T (RD13-01) cells for relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in a phase I clinical trial presented at the 64th American Society of Hematology Annual Meeting and Exposition
02 Dec 2022 Status changed from not stated to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com